Clinical trials: Hypereosinophilic Syndrome
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma, Eosinophilic Asthma
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed…
- Trial name
- NCT04674137
- Testing
- XC8 100 mg
- Where
- 18 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Chemlmmune Therapeutics LLC
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.
- Trial name
- CHINOOK (NCT03953300)
- Testing
- Benralizumab
- Where
- 35 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Hypereosinophilic Syndrome
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a…
- Trial name
- NCT02836496
- Testing
- Mepolizumab 300 mg, Active OCS capsules (5 mg prednisolone or prednisone)
- Where
- 43 sites in United States, Argentina and 11 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1.
- Trial name
- NCT05985694
- Testing
- AD17002
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Severe Eosinophilic Asthma
Real World Study With Benralizumab in Severe Asthma in Switzerland
BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1…
- Trial name
- BEEPS (NCT03907137)
- Where
- 12 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma.
- Trial name
- NCT03469934
- Testing
- Etokimab
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- AnaptysBio, Inc.
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study of Mepolizumab Safety Syringe in Asthmatics
This study is aimed to assess the correct real-world use of a safety syringe for the repeat self-administration of mepolizumab SC.
- Trial name
- NCT03021304
- Testing
- Mepolizumab
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Phase III Long-Term Extension Study With Dexpramipexole
The goal of this clinical trial] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 [GINA, 2021] Step 4 or 5 therapy and…
- Trial name
- EXHALE-5 (NCT06388889)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 509 people
- Sponsor
- Areteia Therapeutics
Asthma
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma.
- Trial name
- NCT02135692
- Testing
- Mepolizumab, SOC
- Where
- 114 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia…
- Trial name
- iOUTRUN (NCT05603845)
- Where
- 24 sites in Colombia, Dominican Republic and 6 more
- Volunteers
- 291 people
- Sponsor
- AstraZeneca